Histopathological study on myocardial hypertrophy associated with ischemic heart disease
Related Experiment Videos
1Research Laboratory for Cardiovascular Pathology, Juntendo University School of Medicine, Tokyo, Japan.
Insights
Myocardial hypertrophy in ischemic heart disease is driven by compensatory mechanisms. Fibrosis leads to increased heart weight and left ventricular hypertrophy as the heart works to maintain function despite myocyte loss.
Area of Science:
- Cardiology
- Pathology
- Heart Disease Research
Background:
- Ischemic heart disease (IHD) can lead to significant cardiac remodeling.
- Understanding myocardial hypertrophy in IHD is crucial for managing heart failure.
Purpose of the Study:
- To investigate the mechanisms and characteristics of myocardial hypertrophy in patients with ischemic heart disease.
- To correlate hypertrophy with infarct size, fibrosis, and coronary artery disease severity.
Main Methods:
- Analysis of autopsied hearts from patients with various forms of IHD and controls.
- Examination of biopsied cardiac tissue from patients undergoing coronary-aorta bypass graft surgery.
- Histopathological assessment of myocardial hypertrophy, fibrosis, and myocyte loss.
Main Results:
- Subendocardial infarction cases exhibited the most pronounced myocardial hypertrophy.
- Hypertrophy correlated directly with the extent of infarction and fibrosis, and left ventricular dilatation.
- Increased heart weight and uniform hypertrophy of residual myocytes were observed despite myocyte loss.
Conclusions:
- Myocardial hypertrophy in IHD is a compensatory response to myocyte loss and fibrosis.
- Fibrosis, rather than coronary artery stenosis severity, is a key driver of hypertrophy.
- This adaptive mechanism aims to maintain cardiac output in the presence of damaged myocardium.
Abstract:
The mode and causes of myocardial hypertrophy occurring in association with ischemic heart disease were studied. The investigation involved autopsied hearts (15 cases of subendocardial infarction, 27 of transmural infarction, 20 of non-infarcted three vessel disease and 17 controls) and biopsied materials obtained during coronary-aorta bypass graft surgery (23 patients with angina pectoris and 46 with myocardial infarction). The subendocardial infarction group showed most marked myocardial hypertrophy that reflected extensive infarction and fibrosis, dilatation of the left ventricular cavity and the loss of myocytes. Despite a marked decrease in the number of myocyte layers, the residual myocardium of the left ventricle was uniformly hypertrophic, accompanied by an increase in the heart weight. The larger the area of fibrosis, the more marked was myocardial hypertrophy irrespective of the luminal diameter of the responsible coronary artery. These findings indicate that myocardial hypertrophy associated with ischemic heart disease is enhanced by the compensatory mechanisms for a decrease in the contractile myocardium due to fibrosis.